Elevation Pharma Inks $17 Million
San Diego-based Elevation Pharmaceuticals has drawn down a $17 million second tranche of its Series A financing. The biopharmaceutical company which develops new aerosol therapies for patients with respiratory diseases is celebrating positive results of a Phase 2a study and has initiated a Phase 2b study. All of the original participants in the Series A financing participated in the $17 million second tranche. These included Canaan Partners, Care Capital, TPG Biotech, and Mesa Verde Venture Partners.
27 September 2011•5 mins read
